GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsJuly 25, 2018-- Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun ina Phase I clinical study to compare the pharmacokinetics and safety of BAT1806, a proposed biosimilar of Actemra® (tocilizumab), to ...
In March 2018, BAT4306F, the recombinant glycosylation-modified anti-human-CD20 monoclonal antibody solution for injection, approved for phase I clinical trials in China. BAT4306Fis a next generation anti-CD20 monoclonal antibody. The CD20 receptor i...
GUANGZHOU, CHINA, March 29, 2018 – Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2018 American ...